Well tbh i think he's probably far better placed to form that view, with his educational gounding in radiopharma at PhD level, and a significant professional background in the same space. Of course its in his best interest to state that but I'd rather accept his view to someone that has no professional background in this space.
Ann: Last patient assessment completed for SARTATE trial, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.38 |
Change
-0.280(6.01%) |
Mkt cap ! $1.628B | |||
| Open | High | Low | Value | Volume |
| $4.62 | $4.65 | $4.30 | $18.54M | 4.185M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14980 | $4.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.39 | 2500 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |